Contact Us
We're here from 9 am to 8 pm ET.
800.963.1778
LUCENTIS 0.5 mg Prefilled Syringe

THE EFFICACY AND SAFETY OF LUCENTIS IS PREFILLED

LUCENTIS® (ranibizumab injection) 0.5 mg prefilled syringe

LUCENTIS 0.5 mg is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO) and myopic choroidal neovascularization (mCNV).

Contact your Franchise Program Manager to learn about updates to our purchasing programs for the LUCENTIS 0.5 mg prefilled syringe.

Committed to helping you and your patients access LUCENTIS 0.5 mg prefilled syringe

Clinical
Specialist

Field
Reimbursement
Manager

Franchise
Program Manager

Contact now

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

LUCENTIS is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS. Hypersensitivity reactions may manifest as severe intraocular inflammation.

WARNINGS AND PRECAUTIONS

Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract. Proper aseptic injection technique should always be utilized when administering LUCENTIS. Patients should be monitored following the injection to permit early treatment, should an infection occur.

Increases in intraocular pressure (IOP) have been noted both pre-injection and post-injection (at 60 minutes) with LUCENTIS. Monitor intraocular pressure prior to and following intravitreal injection with LUCENTIS and manage appropriately.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

ADVERSE EVENTS

Serious adverse events related to the injection procedure that occurred in <0.1% of intravitreal injections included endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract.

In the LUCENTIS Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough.

For additional safety information, please see LUCENTIS full prescribing information.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.